Wein, W;Röper, B;Navab, NAutomatic registration and fusion of ultrasound with CT for radiotherapyLECT NOTE COMPUT SCI20053750303-311
Kaulich, TW;Zurheide, J;Haug, T;Nüsslin, F;Bamberg, MClinical quality assurance for 106Ru ophthalmic applicators.Radiother Oncol200576186-92
Baum, C;Birkner, M;Alber, M;Paulsen, F;Nüsslin, FDosimetric consequences of the application of off-line setup error correction protocols and a hull-volume definition strategy for intensity modulated radiotherapy of prostate cancer.Radiother Oncol200576135-42
Andratschke, N;Nieder, C;Stark, S;Grosu, A;Wiedenmann, N;Busch, R;Kneschaurek, P;Molls, MIntracranial arteries as organs at risk in fractionated stereotactic and intensity-modulated radiotherapy for skull base tumorsEur J Cancer20053 Suppl. S2412-412
Cai, L;Weber, W;Andratschke, N;Astner, S;Schill, S;Busch, R;Schwaiger, M;Nieder, CA model of experimental kidney irradiation for screening of response modifiers: evaluation of insulin-like growth factor-1 (IGF-1) and a chemical p53 inhibitorEur J Cancer20053 Suppl. S2395-395
Röper, B;Nuse, N;Zimmermann, FB;Pigorsch, S;Busch, R;Nährig, J;Molis, MSonographic maximal malignancy criteria count (MMCC) of lymph nodes predicts progression and survival in H&N cancer stage IVA - a new prognostic factorEur J Cancer20053 Suppl. S2306-306
Thamm, R;Geinitz, H;Zimmermann, F;Andratschke, C;Busch, R;Molis, MEffectiveness and side effects of conformal radiation therapy after radical prostatectomy for prostate cancerEur J Cancer20053 Suppl. S2239-239
Golclne, G;Zimmermann, F;Becker, G;Wachter, S;Geinitz, H;Feldmann, H;Poetzi, R;Bamberg, M;Molis, M;Poetter, RProctitis after 3D-conformal radiotherapy of localised prostate cancer classification according to the Eur J Cancer20053 Suppl. S2238-238
Geinitz, H;Zimmermann, F;Scholz, C;Prause, N;Winkler, C;Keller, M;Busch, R;Molis, MLongitudinal evaluation of quality of life and rectal toxicity in patients with conformal radiation therapy for prostate cancerEur J Cancer20053 Suppl. S2232-233
Nieder, C;Andratschke, N;Grosu, A;Thamm, R;Molls, MTumor volume reduction from 3 Gy-fractions measured in brain metastases and implications for clinical trials of response modifiersEur J Cancer20053 Suppl. S2140-141
Login
